Nucleic Acid Delivery Nanotechnologies for
cell programming
gene delivery
gene therapy
nanoparticles
nucleic acid delivery
viral vectors
Journal
ACS applied bio materials
ISSN: 2576-6422
Titre abrégé: ACS Appl Bio Mater
Pays: United States
ID NLM: 101729147
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
30
1
2024
Statut:
aheadofprint
Résumé
In medicine, it is desirable for clinicians to be able to restore function and imbue novel function into selected cells for therapy and disease prevention. Cells damaged by disease, injury, or aging could be programmed to restore normal or lost functions, such as retinal cells in inherited blindness and neuronal cells in Alzheimer's disease. Cells could also be genetically programmed with novel functions such as immune cells expressing synthetic chimeric antigen receptors for immunotherapy. Furthermore, knockdown or modification of risk factor proteins can mitigate disease development. Currently, nucleic acids are emerging as a versatile and potent therapeutic modality for achieving this cellular programming. In this review, we highlight the latest developments in nanobiomaterials-based nucleic acid therapeutics for cellular programming from a biomaterial design and delivery perspective and how to overcome barriers to their clinical translation to benefit patients.
Identifiants
pubmed: 38288693
doi: 10.1021/acsabm.3c00886
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM